← Back to Search

Monoclonal Antibodies

Rosnilimab for Alopecia Areata (AZURE Trial)

Phase 2
Recruiting
Research Sponsored by AnaptysBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 24
Awards & highlights

AZURE Trial Summary

This trial found that the drug rosnilimab was effective and safe in treating moderate to severe alopecia areata.

Eligible Conditions
  • Alopecia Areata

AZURE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Alopecia

AZURE Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Rosnilimab (ANB030)Experimental Treatment1 Intervention
ANB030 biological humanized monoclonal antibody, SC injections every 4 weeks
Group II: Placebo solutionPlacebo Group1 Intervention
Placebo solution, SC injections every 4 weeks

Find a Location

Who is running the clinical trial?

AnaptysBio, Inc.Lead Sponsor
16 Previous Clinical Trials
1,603 Total Patients Enrolled
Bruce Randazzo, MDStudy DirectorAnaptysBio, Inc.
10 Previous Clinical Trials
774 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research encompass participants aged fifty-five and older?

"The participant criteria for this trial requires those aged 18 and above, but not yet 75."

Answered by AI

Has Rosnilimab attained regulatory authorization from the FDA?

"As Rosnilimab is only in its second phase of clinical trials, our team at Power believe it to be moderately safe and assign a safety rating of 2. Unfortunately no efficacy data has been collected yet."

Answered by AI

Who would be an appropriate candidate to take part in this scientific experimentation?

"This medical trial is currently accepting 45 participants of legal age (18 to 75 years old) who have been diagnosed with alopecia areata. Furthermore, the potential candidates must be either male or nonpregnant and nonlactating female individuals, having experienced a SALT score ≥ 50 for more than 24 weeks but no longer than 8 years from onset."

Answered by AI

Are there any vacancies for participants in this research program?

"Data housed on clinicaltrials.gov shows that this research initiative is still active and recruiting patients, with the trial being first advertised in December 2021 and recently updated in early May 2022."

Answered by AI

In how many locations are the participants of this trial being recruited?

"This investigation is running out of a total 17 locations, with 3 being Site 10-106 (Tulsa, Oklahoma), Site 10-101 (Charlotte, North carolina) and 10-107 (Upper Saint Clair, Pennsylvania)."

Answered by AI

To what extent is this clinical trial being populated?

"In order to properly evaluate the efficacy of this protocol, 45 participants who match the inclusion criteria must be enrolled. AnaptysBio Inc., which is responsible for overseeing this trial, will draw from two sites: Site 10-106 in Tulsa, Oklahoma and Site 10-101 in Charlotte, North carolina."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
Texas
How old are they?
18 - 65
What site did they apply to?
Site 10-108
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
2021. "A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05205070.
All > Androgenetic Alopecia > Alopecia Areata
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top